MI Sign Up for eTOC Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Molecular Interventions 8:36-49, (2008)
© American Society for Pharmacology and Experimental Therapeutics
10.1124/mi.8.1.8
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Newman, R. A.
Right arrow Articles by Block, K. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Newman, R. A.
Right arrow Articles by Block, K. I.
Reviews

Cardiac Glycosides as Novel Cancer Therapeutic Agents

Robert A. Newman1, Peiying Yang1, Alison D. Pawlus1 and Keith I. Block2

1 Department of Experimental Therapeutics and Pharmaceutical Development Center, University of Texas, M. D. Anderson Cancer Center, Houston, TX 77054;
2 Institute for Integrative Cancer Care, Evanston, IL 60201


Formula

The class of steroid-like compounds designated cardiac glycosides includes well-known drugs such as digoxin, digitoxin, and ouabain. Their continued efficacy in treatment of congestive heart failure and as anti-arrhythmic agents is well appreciated. Less well known, however, is the emerging role of this category of compounds in the prevention and/or treatment of proliferative diseases such as cancer. New findings within the past five years have revealed these compounds to be involved in complex cell-signal transduction mechanisms, resulting in selective control of human tumor but not normal cellular proliferation. As such, they represent a promising form of targeted cancer chemotherapy. New clinical studies of their anticancer potential as single or adjuvant treatments may provide insight into these potentially valuable therapeutic options. This review focuses on recent findings on cellular pharmacology of cardiac glycosides as they relate to treatment of human cancer and attempts to explain why these agents have been overlooked in the past.




This article has been cited by other articles:


Home page
 IOVSHome page
C. Antczak, C. Kloepping, C. Radu, T. Genski, L. Muller-Kuhrt, K. Siems, E. de Stanchina, D. H. Abramson, and H. Djaballah
Revisiting Old Drugs as Novel Agents for Retinoblastoma: In Vitro and In Vivo Antitumor Activity of Cardenolides
Invest. Ophthalmol. Vis. Sci., July 1, 2009; 50(7): 3065 - 3073.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Tian, X. Li, M. Liang, L. Liu, J. X. Xie, Q. Ye, P. Kometiani, M. Tillekeratne, R. Jin, and Z. Xie
Changes in Sodium Pump Expression Dictate the Effects of Ouabain on Cell Growth
J. Biol. Chem., May 29, 2009; 284(22): 14921 - 14929.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
A. Y. Bagrov, J. I. Shapiro, and O. V. Fedorova
Endogenous Cardiotonic Steroids: Physiology, Pharmacology, and Novel Therapeutic Targets
Pharmacol. Rev., March 1, 2009; 61(1): 9 - 38.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Zhang, D. Z. Qian, Y. S. Tan, K. Lee, P. Gao, Y. R. Ren, S. Rey, H. Hammers, D. Chang, R. Pili, et al.
Inaugural Article: Digoxin and other cardiac glycosides inhibit HIF-1{alpha} synthesis and block tumor growth
PNAS, December 16, 2008; 105(50): 19579 - 19586.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.